Medsamic (Tranexamic Acid)

• Tranexamic Acid is an antifibrinolytic used to reduce bleeding in several clinical settings.
• Hemophilia: reduces the frequency and severity of bleeding episodes in patients with hemophilia.
• Menorrhagia: decreases menstrual blood loss and improves quality of life for women with heavy periods.
• Surgical procedures: helps prevent intra‑operative and post‑operative bleeding in patients undergoing various surgeries.

• Tranexamic Acid competitively inhibits the activation of plasminogen to plasmin by binding to lysine‑binding sites on plasminogen. This blocks the breakdown of fibrin clots, thereby reducing fibrinolysis and stabilizing formed clots. By preserving the integrity of the fibrin matrix, the drug supports hemostasis during trauma or surgical insult, and its effect is dose‑dependent and reversible upon discontinuation.

Tranexamic Acid may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea
• Vomiting
• Headache
• Dizziness
• Injection site pain

Serious or Rare Side Effects

• Thromboembolic events (deep vein thrombosis, pulmonary embolism)
• Seizures
• Visual disturbances (blurred vision, retinal changes)
• Severe allergic reactions (anaphylaxis, angioedema)

• When using Tranexamic Acid, clinicians should consider several precautionary measures to ensure safe administration.
• Renal impairment: adjust dose or avoid use in severe renal dysfunction.
• History of thromboembolism: avoid or use with caution due to clot risk.
• Concomitant anticoagulants: monitor coagulation parameters closely.
• Pregnancy: use only if potential benefit justifies potential risk to the fetus.
• Pediatric use: safety and efficacy not established; use under specialist supervision.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Tranexamic Acid can interact with other medicines, influencing clotting or bleeding risk.

Major Interactions (Avoid)

• Concurrent use with thrombolytic agents (e.g., alteplase): may reduce therapeutic effect of thrombolysis.
• Direct oral anticoagulants (e.g., rivaroxaban, apixaban): increased risk of thrombosis.
• Procoagulant factor concentrates (e.g., activated factor VII): heightened clot formation risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive bleeding risk if not adequately controlled.
• Antiplatelet agents (e.g., aspirin, clopidogrel): may diminish antiplatelet effect.
• Diuretics: potential for altered plasma concentration; monitor renal function.
• Hormonal contraceptives containing estrogen: possible increased thrombotic risk.